Treatment of Hepatic Metastases from Gastric or Gastroesophageal Adenocarcinoma with Computed Tomography-guided High-dose-rate Brachytherapy (CT-HDRBT)

• Published in: Anticancer research 2012-12, Vol.32 (12), p.5453-5458
• Main Authors: GEISEL, Dominik, DENECKE, Timm, COLLETTINI, Federico, GRIESER, Christian, WUST, Peter, THUSS-PATIENCE, Peter, HAMM, Bernd, GEBAUER, Bernhard
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Adenocarcinoma - secondary; Aged; Aged, 80 and over; Biological and medical sciences; Brachytherapy - adverse effects; Brachytherapy - methods; Esophageal Neoplasms - pathology; Esophageal Neoplasms - radiotherapy; Follow-Up Studies; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Liver Neoplasms - radiotherapy; Liver Neoplasms - secondary; Medical sciences; Middle Aged; Radiography, Interventional - adverse effects; Radiography, Interventional - methods; Retrospective Studies; Stomach Neoplasms - pathology; Stomach Neoplasms - radiotherapy; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tomography, X-Ray Computed - adverse effects; Tomography, X-Ray Computed - methods; Treatment Outcome; Tumors
• ISSN: 0250-7005; 1791-7530

This retrospective analysis was performed to evaluate the clinical outcome of patients with hepatic metastases from gastric or gastroesophageal adenocarcinoma who were treated with computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT). Eight patients with a total number of 12 isolated hepatic metastases from histologically-proven adenocarcinoma of the lower oesophagus or stomach, were treated with CT-HDRBT. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) was performed 6 and 12 weeks after CT-HDRBT and then every 3 months to evaluate treatment efficacy. The median follow-up time was 6.1±6.8 months. Lesion size ranged from 14 to 68 mm in diameter with a median of 46±21 mm. No patient developed a local recurrence. Five patients developed systemic progression after a median time of 3.7±3.6 months (three in the liver, one in liver and bone and one in liver and resection margin from gastrectomy). One patient died 3.4 months after CT-HDRBR because of liver progression with cholestasis. No major complications associated with the treatment occurred. CT-HDRBT might be a feasible alternative to surgical resection of liver metastases from gastric or gastroesophageal adenocarcinoma in selected patients and seems to have similar outcome rates as surgical resection in our small collective.